Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$208.00K$208.00K— vs Q3 2020 Net Income-$14.04M-$14.04MN/M vs Q3 2020 EPS Diluted-$1.25-$1.25N/M vs Q3 2020 Operating Income-$14,134,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,061,000N/M Margins · derivedOperating margin-6795.2%
Net margin-6751.4%
ended Sep 30, 2021 · filed Nov 5, 2021 · 36 d after period end